Lexicon Pharmaceuticals | LXRX - Ingresos Por Ventas





Ventas Cambio Fecha
Abbott USD 12.59B 1.43B 2026-06
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
AstraZeneca USD 15.38B 90M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
Halozyme Therapeutics USD 481M 104M 2026-06
Illumina USD 1.16B 70M 2026-06
Insmed USD 425.49M 119.53M 2026-06
Ironwood Pharmaceuticals USD 113.04M 6.53M 2026-06
J&J USD 25.31B 1.21B 2026-06
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
MannKind USD 109.37M 19.17M 2026-06
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Novartis USD 14.41B 1.3B 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Thermo Fisher Scientific USD 11.99B 980M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
United Therapeutics USD 783.3M 1.8M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12